88 results about "Drug application" patented technology

The invention discloses a skin anti-infection medicine applying device, and relates to the field of medical smearing medicine applying appliances, the skin anti-infection medicine applying device comprises a shell, the shell is provided with a handle, the handle is provided with an opening, and the handle is rotatably connected with a driving part capable of covering the opening. The roller assembly comprises a pair of roller frames which are arranged in parallel, each roller frame is provided with a U-shaped groove used for being rotationally connected with a smearing roller, the two sides of each U-shaped groove are further oppositely connected with limiting rods in a sliding mode, and the limiting rods are connected to the roller frames through springs. Ointment is extruded out through the extrusion assembly and conveyed and smeared to the infected part of a patient, it is reduced that limbs of the patient make contact with ointment smearing, and therefore infection is reduced. Meanwhile, the medicine is automatically extruded and smeared, so that the uniformity of medicine smearing is improved.

The present invention pertains to the technical field of drug application and particularly relates to clinical use of a KRAS G12D inhibitor. The inhibitor can be clinically used to effectively treat patients with advanced solid tumors carrying the KRAS G12D mutation and can produce beneficial effects.

The invention provides a combined medicine recommendation method based on multi-modal alignment. A core module of the recommendation method comprises a cloth perception multi-modal medicine alignment module, a time sequence multi-view patient aggregation module and a combined medicine recommendation module. According to the recommendation method, electronic health records EHRs serve as a data source, multi-modal information matched with physical signs of a patient and medicine application characteristics is obtained, effective alignment and fusion are conducted on the multi-modal information through the core module, and suggestion data matched with the multi-modal information and composed of multiple medicines are generated. A DDI loss function and a dynamic weighting strategy are introduced to process conflicts among different drugs in the generated suggestion data so as to output safe suggestion data, and it is avoided that conflicting drugs are recommended in the suggestion data; according to the method, personalized, high-safety, scientific and reasonable drug combination suggestions can be provided.

The invention discloses a method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin, and relates to the technical field of drug application, and the method comprises the following steps: obtaining pre-drug patient information before treatment of a patient with oxaliplatin and clinical feature data after use; processing and feature analysis are carried out based on pre-drug patient information and clinical feature data, and a core feature data set related to neurotoxin is determined; and based on the core feature data set, predicting the oxaliplatin-induced peripheral neurotoxicity of the patient by adopting a pre-trained gradient boosting decision tree model, and outputting a prediction risk result. According to the method, the occurrence risk of peripheral neurotoxicity can be accurately predicted according to clinical indexes so as to guide clinical accurate medication.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

The present application belongs to the technical field of hair loss treatment, and particularly relates to a phototherapy and drug synergistic intervention system for androgenetic alopecia of human scalp. In the system, the drug is angelica extract with a concentration of 0.1-500 ug / mL; the phototherapy light source is a red light LED light source with a wavelength of 600-700 nm; the light irradiance is 2-100 mW / cm 2 ; the light dose is 2-20 J / cm 2 ; the irradiation mode is steady light or pulsed light; and the synergistic intervention mode is that the phototherapy and the drug application are performed synchronously or the phototherapy is performed within 0.5-2 hours after the drug application. Experiments show that the light-drug combined intervention significantly improves cell viability, ATP level, migration ability, IGF1 and VEGF secretion, reduces ROS and MDA levels, inhibits Caspase-3 activity, regulates BCL2 / BAX expression, activates Wnt, Hh and PI3K pathways, and inhibits BMP and TGF-beta pathways. The present application provides a treatment scheme with clear timing and standardization, and realizes safe, non-invasive and efficient hair loss treatment.

The invention belongs to the technical field of biotechnology, and particularly relates to application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit and a detection method. The invention provides an application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit for liver cirrhosis diagnosis / treatment and a detection method of a serum exosome MZF1 protein. The exosome MZF1 protein is used as a marker, a valuable reagent or drug application prospect is provided for early diagnosis and treatment of liver cirrhosis, and help is provided for analysis of more serum exosome proteins applied to liver cirrhosis markers.

The application discloses a method for calculating the area of pesticide application. The method comprises the following steps: obtaining the motion trajectory of a pesticide application device, and intercepting a third trajectory located in a first area to be applied with pesticide; obtaining a radiation range according to the third trajectory and the pesticide application range, and performing color processing; calculating the area after color processing to obtain the pesticide application area, and judging the pesticide application condition in combination with a target area. In addition, after the pesticide application is completed, a trajectory point is randomly selected as a detection position, and a corresponding plant image is required to be uploaded for verification. The application solves the area calculation problem of irregular areas and overlapping spraying through a color algorithm, and realizes precise quantitative evaluation and anti-fraud supervision of the pesticide application quality in combination with a random inspection mechanism.

The invention belongs to the technical field of immunology, and discloses an anti-human CD19 receptor single-domain antibody, and the amino acid sequence of the single-domain antibody is as shown in SEQ ID No.1. The antibody has good reaction activity with human CD19, can be used for detecting or diagnosing CD19 and treating related diseases with abnormal CD19 expression, and has wide application prospects in the fields of drug application, clinical detection and diagnosis and the like.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The application relates to application of C-methylated high isoflavone compounds in preparation of antitumor drugs and belongs to the technical field of drug application. In order to solve the problem that the existing antitumor activity is not much reported, the application of C-methylated high isoflavone compounds in preparation of antitumor drugs is provided, the C-methylated high isoflavone compounds are selected from compounds shown in the following formula 1 or formula 2: the C-methylated high isoflavone compounds or pharmaceutically acceptable salts thereof are used as active ingredients for preparation of antitumor drugs for preventing and / or treating adrenal pheochromocytoma (PC-12) and / or human brain astrocytoma (U-87MG). The C-methylated high isoflavone compounds have the advantages of high activity and high inhibition capacity, can be extracted from polygonatum sibiricum and have good drug safety.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition of mupirocin ointment and a preparation method of the pharmaceutical composition. The invention aims to solve the problem that the existing mupirocin ointment only pays attention to stability and neglects skin barrier repair, so that treatment and healing are disjointed. The composition comprises mupirocin, chitosan and the like, and is characterized in that a multiphase microstructure system is constructed, glyceryl monostearate provides hydrophobic protection for mupirocin, and lactic acid activates chitosan. The preparation method adopts three-stage temperature control synchronous homogeneous curing. The invention solves or at least alleviates the inherent defect that in the prior art, a mupirocin ointment preparation only focuses on the chemical stability of a medicine but neglects the biological requirement of skin barrier repair of a medication part, and provides a pharmaceutical composition of a mupirocin ointment and a preparation method thereof.

The invention relates to an aquacide microsphere preparation and a preparation method thereof, aquacide is entrapped in a polylactic acid-glycolic acid copolymer carrier through a W / O / W type re-emulsification-solvent evaporation method, the microsphere preparation is prepared, slow and continuous release of drugs can be realized, the lasting period is prolonged, the drug application frequency is reduced, and the drug wastage rate and the environmental risk are reduced; meanwhile, the pesticide is in a solid state, is suitable for long-distance transportation, can be redissolved before being used, and has important practical application and commercial values.

The application discloses a kind of saving type synchronous oiling and dosing methods for drug application unmanned aerial vehicle, including two feeding nozzles arranged on the material adding unmanned aerial vehicle and drug application oil tank and drug application tank arranged on the drug application unmanned aerial vehicle;The structure of drug application oil tank and drug application tank is same, and it includes box, leakage-proof sealing film, one-way pressure door and liquid leakage collection box;Feeding nozzle includes outer tube and inner tube arranged in outer tube, and the end of outer tube is inserted into the through hole of liquid leakage collection box after passing through the flow channel, and the open end of inner tube faces automatic telescopic structure, and automatic telescopic structure drives automatic support mechanism to extend into the inner side of inner tube, and after electric support mechanism drives the support claw of itself to open, it is supported on the inner wall of inner tube;The application solves the problem that the existing drug application unmanned aerial vehicle repeatedly lifts to add oil and medicine, resulting in low work efficiency, and the problem of supply waste and environmental pollution caused by material leakage when the material adding unmanned aerial vehicle supplies the drug application unmanned aerial vehicle in the air.

The invention relates to a novel method for reducing drug-induced cell death, and belongs to the technical field of biological medicines. LP-Rh2 in the form of lipidosome is prepared by providing a skeleton structure by lipidosome and taking ginsenoside Rh2 as a functional component, and after LP-Rh2 and other drugs are jointly added into a cell culture system, the drug-induced cytotoxicity can be inhibited in various scenes, the cell viability is improved, and the drug-induced cytotoxicity can be inhibited. Therefore, the action mechanism of other candidate drugs with cytotoxicity can be better matched and researched in scientific research application, and potential safety risks possibly brought by drugs, especially vaccine adjuvants, can be reduced in drug application.

The invention discloses a compound serving as an AKR1C3 (aldoketoreductase 1C3) inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The compound has a structure shown in a formula I or a pharmaceutically acceptable salt thereof; wherein when R1 is carboxyl, A is a nitrogen-containing saturated aromatic ring, and B is an unsaturated aromatic ring or an unsaturated heterocyclic ring; when R2 is carboxyl, B is an unsaturated aromatic ring, and A is a condensed ring containing a nitrogen-containing saturated aromatic ring. The piperidinecarboxylic acid compound or benzoic acid compound and the pharmaceutically acceptable salt thereof provided by the invention can selectively inhibit the activity of AKR1C3, have a remarkable inhibition effect, achieve the effect of preventing and treating prostatic cancer through a final step of inhibiting the generation of androgen in tumor cells, can be prepared into a medicine for treating AKR1C3 related diseases, and have a wide application prospect. Particularly, the compound is applied to preparation of a medicine for treating prostatic cancer. Formula I.

The application relates to a dihydropyridine small-molecule compound and a preparation method and application thereof in preparing a drug for treating neuroblastoma, and belongs to the technical field of drug preparation. The application discloses a dihydropyridine small-molecule compound, a structural formula of which is as shown in the description, which can be used for preparing a drug for treating neuroblastoma with high ALDH18A1 expression, can effectively solve the problems of poor water solubility of YG1702, low inhibition rate of neuroblastoma and other drug application problems, and has a good application prospect.

The utility model relates to the field of medicine applying devices, in particular to a medicine applying auxiliary device which comprises a device base, at least one inserting installation position is arranged at the top of the device base, an installation inserting rod is inserted in the inserting installation position, and a medicine applying assembly is hinged to the end of the installation inserting rod in a ball mode. The medicine smearing assembly comprises a connecting handle, a medicine smearing handle and a mounting base, one side of the connecting handle is spherically hinged to the end of the mounting insertion rod, the mounting base and the medicine smearing handle are connected to the two ends of the other side of the connecting handle respectively, and a refraction plate is fixed between the medicine smearing handle and the connecting handle; a mounting plate is hinged to the mounting base, the medicine smearing assembly is inserted into the device base through a mounting insertion rod, a patient holds a medicine smearing handle to drive the mounting plate to move in multiple directions, and medicine smearing on the back of the patient is achieved; the position of the mounting plate is obtained through the refraction plate between the connecting handle and the medicine smearing handle, and the patient is helped to accurately control the mounting plate through the medicine smearing handle.

The invention discloses a vagina medicine applying device for gynecological patients. The vagina medicine applying device comprises a pulling medicine applying device and a clamping pushing component. The invention belongs to the field of medical instruments, and particularly relates to a vagina medicine applying device for gynecological patients. The device serves as a gynecological vagina local drug delivery instrument, through optimization of a mechanical structure and integration of functions, technology upgrading and function innovation of a traditional vagina applicator are achieved, the industry current situation that a traditional gynecological drug application instrument is single in function and extensive in operation is broken through, triple improvement of the treatment effect, the use experience and the operation safety is achieved, and the device is worthy of popularization and application. A more efficient, safer and more humanized dosing tool is provided for gynecological clinical nursing, and the overall service quality of gynecological nursing can be improved.

This utility model discloses a drug application spraying device for applying medicine to the surface of a yak, including a handheld handle with several spray tubes arranged side by side at one end and a medicine inlet tube at the other end; a roller rotatably mounted on the outer side of the end of the spray tubes, with its axis parallel to the arrangement direction of the spray tubes; the end of each spray tube has an axially movable ball head. When the end of the spray tube contacts the yak's surface, the ball head is pressed and retracts into the tube, opening the spray passage; when the pressure is released, the ball head returns to its original position and presses against the sealing surface of the end of the spray tube, closing the spray passage. This spraying device, through the several spray tubes at the end of the handheld handle, allows for easy contact with the yak's surface and penetration into the hair, pushing the ball head back into the spray tube to achieve drug application. This avoids the problem of the medicine not being able to penetrate the hair and contact the surface during long-distance spraying. Furthermore, the roller can roll on the yak's surface, ensuring uniform application of the medicine.

The application provides an analgesic hemostatic agent and a preparation method thereof, and belongs to the technical field of medicines. A decellularized material is coupled with a snake venom thrombin and ibuprofen, embedded in a pH-responsive polymer to prepare pH-responsive microspheres, and added into a temperature-sensitive hydrogel together with a traditional Chinese medicine fermentation product to prepare an analgesic hemostatic agent water agent. Porous calcium carbonate microspheres with fixed solid acid are mixed with hydroxyapatite to prepare a spray analgesic hemostatic agent powder, which is used in combination with the analgesic hemostatic agent water agent to prepare the analgesic hemostatic agent. The analgesic hemostatic agent prepared by the application adopts a combination of the powder and the water agent, can better maintain the drug activity, has good hemostatic, analgesic, anti-inflammatory and antibacterial effects, and has a slow and controlled release and a long-acting effect, so that the drug application amount is reduced, the patient compliance is improved, and the analgesic hemostatic agent has a wide application prospect.

The invention discloses polygalacturonic acid (PGA) and application of a neohesperidin dihydrochalcone (NHDC) or neohesperidin (NH) embedded compound of the polygalacturonic acid (PGA) in preparation of anti-allergic food or drugs. The PGA has good biocompatibility and immune regulation and intestinal barrier repair functions. Experiments show that the PGA can significantly reduce IgE-mediated food anaphylaxis, alleviate allergic symptoms and improve intestinal structures. PGA is adopted as a carrier, and the PGA and NHDC / NH form non-covalent binding through intermolecular force to prepare the PGA-NHDC / PGA-NH compound, so that the solubility and the stability of the NHDC / NH are improved, and a synergistic anti-allergic effect is also generated. The PGA-NHDC / PGA-NH compound has the advantages of small molecular weight, fast absorption and non-immunogenicity, and can release NHDC / NH in colon in a targeted manner. On the basis, the invention further provides the application of the PGA-NHDC / PGA-NH compound in preparation of the orange juice, the obtained juice system is in a stable suspension state, has no precipitation layering phenomenon, has targeted synergistic antianaphylaxis and high storage stability, and remarkably improves the functionality and the storage stability of the juice.

1. Name of the product in this design: Drug uniform application device. 2. Purpose of this design: This design is a drug application device for evenly applying ointments or drugs to the affected area. 3. The key design features of this product are its overall shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

The invention belongs to the technical field of pesticide disinfestation, and discloses an insecticidal composition and application thereof.The insecticidal composition comprises an active component A and an active component B. The active component A is a compound shown in the formula I (formula I), and the active component B is any one of a compound shown in the formula II (formula II) or a compound shown in the formula III (formula III); the mass ratio of the active component A to the active component B is (1: 50)-(50: 1). According to the insecticidal composition disclosed by the invention, insecticides with different action mechanisms are compounded to form a complementary effect, so that the control effect is improved, the adaptation difficulty of pests can be increased, and the development of drug resistance is delayed. Through compounding, multiple treatment effects can be realized by one drug, and the drug application frequency is reduced.

This invention relates to the field of deep-sea mining hose cleaning technology, specifically to an intelligent robot and method for cleaning adsorbed organisms on deep-sea mining hoses. The robot includes two shells, with a power storage compartment inside each shell for storing power. It also includes a visual drug application device for monitoring bioadsorption on the mining hose and performing preliminary drug treatment, a vortex-flow erosion device for further treatment of adsorbed organisms, a positioning and detection device for monitoring the treated mining hose, treating stubborn residual adsorbents, and monitoring the overall condition of the mining hose, an AUV thruster, and a communication control device. The communication control device includes an ACN underwater acoustic communication module and an intelligent processing module. The invention also includes a cleaning method using this robot. This application features multi-level collaborative cleaning, significantly improving the efficiency of bioadhesion removal, intelligent closed-loop control, and fully autonomous operation, reducing labor costs.

The invention discloses an application of an NAT10-ac4C-mitochondrial-acetyl-CoA regulation axis in diagnosis and treatment of mitochondrial dysfunction and related metabolic diseases, and belongs to the technical field of biology. The regulatory axis systematically regulates the expression of the nuclear coding mitochondrial gene in a physiological state, and maintains a metabolism steady state; the invention also provides a biomarker combination of the regulatory axis. The biomarker combination comprises NAT10 related indexes, ac4C modification level of nuclear coding mitochondrial gene mRNA and acetyl coenzyme A level, and can be used for diagnosis and prognosis evaluation of mitochondrial dysfunction and related metabolic diseases. Meanwhile, the invention further provides a drug screening method, a treatment method and related drug application based on the regulation axis, systematic diagnosis and universal treatment of mitochondrial dysfunction related diseases are achieved, and the regulation axis has important clinical transformation value.

The invention relates to a neck vagus nerve stimulation device and a preparation method thereof. The neck vagus nerve stimulation device comprises a base body, an electrical stimulation unit and a drug delivery application. The electrical stimulation unit comprises a pulse generation module and an electrode connected with the pulse generation module, the electrode can release stimulation current to the skin of the human body, and at least the electrode is arranged on the base body. The drug delivery patch is arranged on the base body, and the drug delivery patch comprises a drug which can be absorbed through the skin. Wherein the base body is suitable for being attached to the neck skin of a human body, so that the electrodes and the administration application are in contact with the neck skin, and the electrical stimulation signals and the drug efficacy act on a target neck area through the neck skin. The neck vagus nerve stimulation device is compact in structure, portable, easy to use, low in cost and capable of enhancing the treatment effect.

The disadvantage of a coating-type microneedle is that it is difficult to coat a large amount of a drug on the microneedle, and thus the effective use of the drug is limited. The present invention eliminates the disadvantage of the coating-type microneedle. A drug application type microneedle array is characterized by comprising a substrate and a plurality of microneedles, and the microneedles are arranged on the substrate in such a manner that at least three microneedles form a group to form a space and thereby provide a drug application part in the space.

The invention provides a 2-seleno-N-substituted quinazolinone compound as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis. The 2-seleno-N-substituted quinazolinone compound has a structure as shown in a formula I which is described in the specification. The 2-seleno-N-substituted quinazolinone compound provided by the invention has potential drug activity and a drug application prospect. Compared with a preparation method in the prior art, the preparation method provided by the invention has the advantages of simple conditions, easiness in control, high reaction efficiency, economical steps, cheap and easily available raw materials, no ligand, no oxidant, good functional group tolerance and the like, and the prepared 2-seleno-N-substituted quinazolinone compound has relatively high purity which can reach 99.9% and is suitable for industrial production. And the method has a relatively high market popularization value. Compared with a multi-step synthesis reaction, a target product can be obtained through one-step reaction, the reaction yield reaches 51%, and the method has the advantages that steps are economical and the like.